Thrombogenics Nv operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Thrombogenics Nv with three other
miscellaneous service companies in Europe:
Pharming Group NV
of the Netherlands
sales of 10.83 million Euro [US$11.48 million]
of which 100%
was Recombinant Proteins),
Circassia Pharmaceuticals PLC
of the United Kingdom
(£10.80 million [US$13.01 million]
of which 95%
was operating-NIOX), and
based in Norway
(99.93 million Norwegian Kroner [US$11.71 million]
During the year ended December of 2015, sales at
Thrombogenics Nv were 11.20 million Euro (US$11.87 million).
decrease of 18.7%
versus 2014, when the company's sales were 13.78 million Euro.